Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $29.38.

KURA has been the topic of a number of recent analyst reports. Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday. UBS Group assumed coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, HC Wainwright raised their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of KURA. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter worth $25,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology in the 3rd quarter worth $146,000. Quarry LP acquired a new stake in shares of Kura Oncology during the second quarter worth $196,000. Erste Asset Management GmbH bought a new stake in Kura Oncology in the third quarter valued at about $215,000. Finally, Bellevue Group AG lifted its stake in Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the period.

Kura Oncology Stock Down 1.3 %

Shares of KURA opened at $10.53 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $15.85 and a two-hundred day moving average price of $18.84. The stock has a market cap of $818.81 million, a price-to-earnings ratio of -4.46 and a beta of 0.75. Kura Oncology has a 12 month low of $9.68 and a 12 month high of $24.17.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.